Progression‐free survival is a weakly predictive surrogate end‐point for overall survival in follicular lymphoma: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Progression‐free survival is a weakly predictive surrogate end‐point for overall survival in follicular lymphoma: A systematic review and meta‐analysis

Published:2024-04-04 Issue:6 Volume:204 Page:2237-2241
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Milrod Charles J.¹^ORCID,Kim Kang Woo²,Raker Christina³^ORCID,Ollila Thomas A.¹^ORCID,Olszewski Adam J.¹^ORCID,Pelcovits Ari¹^ORCID

Affiliation:

1. Department of Hematology/Oncology Brown University Providence Rhode Island USA

2. Warren Alpert School of Medicine Brown University Providence Rhode Island USA

3. Lifespan Biostatistics, Epidemiology, Research Design, and Informatics, Rhode Island Hospital Providence Rhode Island USA

Abstract

SummaryAlthough progression‐free survival (PFS) is a commonly used surrogate end‐point for clinical trials of follicular lymphoma (FL), no analyses have evaluated the strength of surrogacy for PFS with overall survival (OS). A systematic review was performed and 20 studies (total participants, 10 724) met final inclusion criteria. PFS was weakly associated with OS (correlation coefficient; 0.383, p < 0.001). The coefficient of determination was 0.15 (95% CI: 0.002–0.35) suggesting 15% of OS variance could be explained by changes in PFS. This challenges the role for PFS as a surrogate end‐point for clinical trials and drug approvals.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19449

Reference20 articles.

1. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

2. Comparison in low‐tumor‐burden follicular lymphomas between an initial no‐treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte;Brice P;Clin Oncol,1997

3. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

4. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

5. Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989–2016